This is why our scientists need not fear that computers will replace them altogether – in fact more medicinal chemists will be needed if we’re to continue making advances in this field. Already, AI models support our decision-making in drug discovery, but integrating AI into an automated drug design process will require new thinking: it will change the setting, just as the software and technology of recent years has done in predicting properties to a high degree of accuracy much faster than in a lab without automation.
Automating discovery
With ongoing automation, we can foresee computers conducting experiments productively and autonomously with the help of robotics in three to five years’ time. This is indeed already being tested in certain places, particularly at ETH Zurich and in industry. We can also expect AI to predict the effects of substances at an earlier stage of development and suggest new chemical structures with the desired properties. This would mean that fewer substances that turn out not to be effective would need to be tested.
In the long run, AI may hold the key to unlocking the door to more effective and more accessible personalised medicine. But it will take continuing research and investment in this field, and fresh interdisciplinary thinking from experts in the AI, chemistry, pharmaceuticals and biotech domain.